Pfizer in technology licensing deal with Xoma

Share this article:

Drug developer Xoma announced that it has licensed technology to Pfizer that can be used to screen and make antibody products, the Associated Press reported.

Xoma said it will license the technology for an upfront payment of $30 million, along with future royalty and milestone payments.

Xoma also licenses the technology to companies including Merck, Centocor and Alexion Pharmaceuticals. Xoma receives royalties from Genentech for its macular degeneration drug Lucentis because that drug uses its bacterial cell expression technology.

Share this article:
close

Next Article in News

Email Newsletters

More in News

Five things for pharma marketers to know: Friday, August 22

Five things for pharma marketers to know: Friday, ...

Two new indications give Eliquis more juice, a new rule is making hydrocodone harder to get and the ALS Ice Bucket Challenge highlights a controversial aspects of drug discovery and ...

Lilly takes on Amgen's Enbrel

Lilly takes on Amgen's Enbrel

Phase-III tests indicate Lilly's experimental treatment bests Amgen's for moderate-to-severe plaque psoriasis.

GSK Ellipta franchise expands

GSK Ellipta franchise expands

The FDA has approved Arnuity Ellipta for asthma.